DOCSLIB.ORG

Listing of Global Companies with Ongoing Government Activity

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Listing of Global Companies with Ongoing Government Activity COMPANY LINE OF BUSINESS TICKER Q R LABS LTD PHARMACEUTICAL PREPARATIONS QA GROUP, LLC EQUIPMENT RENTAL AND LEASING, NEC QALIAN PHARMACEUTICAL PREPARATIONS QASER ELAG DRUGS COMPANY LIMITED PHARMACEUTICAL PREPARATIONS QATAR PHARMA (I.V. SOLUTIONS) FACTORY PHARMACEUTICAL PREPARATIONS QED BIOSCIENCE, INC BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC QIAGEN INC. DRUGS, PROPRIETARIES, AND SUNDRIES QIAN'AN TANGSHAN HUI'AN PHARMACEUTICAL CO., LTD. PHARMACEUTICAL PREPARATIONS QIANCAOYAN BIOLOGICAL TECHNOLOGY (SHANGHAI) CO., LTD. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC QIANDONG NANZHOU LIKEQING TECHNOLOGY CO., LTD. PHARMACEUTICAL PREPARATIONS QIANDONGNAN PREFECTURE MIAOLING AND MIAO MEDICINE TECHNOLOGY CO., LTD. PHARMACEUTICAL PREPARATIONS QIANFAN MEDICINE CO., LTD. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC QIANGDI NANOMETER ZHEJIANG CO., LTD. PHARMACEUTICAL PREPARATIONS QIANJIANG CITY VETERINARY MEDICINES FACTORY BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC QIANJIANG QIANLONG PHARMACEUTICAL CO., LTD. PHARMACEUTICAL PREPARATIONS QIANJIANG SIWEI AMINO ACID CO., LTD. PHARMACEUTICAL PREPARATIONS QIANJIANG SIWEI AMINO ACID FACTORY PHARMACEUTICAL PREPARATIONS QIANJIANG YONGAN PHARMACEUTICAL CO., LTD. PHARMACEUTICAL PREPARATIONS 002365 QIANNAN BUYI & MIAO AUTONOMOUS PREFECTURE GUIDING HUSANTIE PHARMACEUTICAL CO., LTD. PHARMACEUTICAL PREPARATIONS QIANSHAN COUNTY LIANBANG INDUSTRIAL CO., LTD. PHARMACEUTICAL PREPARATIONS QIANSHAN COUNTY PUTE BRUSH MANUFACTURING FACTORY PHARMACEUTICAL PREPARATIONS QIANSHAN COUNTY SHUZHOU SPECIAL TYPE BRUSH MANUFACTURING FACTORY MEDICINALS AND BOTANICALS, NSK QIANWEI COUNTY BAICAOYUAN TRADITIONAL CHINESE MEDICINE RESOURCE DEVELOPMENT CO., LTD. PHARMACEUTICAL PREPARATIONS QIANXI COUNTY LVYUAN FOODSTUFF DEVELOPMENT CO., LTD. MEDICINALS AND BOTANICALS, NSK QIANYAN BIOLOGICAL TECHNOLOGY CO., LTD. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC QIANYANG COUNTY BAOMA BIOLOGICAL IMMUNITY CO., LTD. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC QIAOJIA COUNTY DONGJUN PHARMACEUTICAL CO., LTD. PHARMACEUTICAL PREPARATIONS QIAOTOU TOWN LINGTOU MEDICINAL MATERIALS PROCESSING FACTORY PHARMACEUTICAL PREPARATIONS QIAOXIN GROUP DONGFANG KANGLIN CO., LTD. PHARMACEUTICAL PREPARATIONS QICHUN COUNTY QIANNIANJIAN CHAIN MEDICINE COMPANY BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC QICHUN MINQIANG GLUE FACTORY BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC QIDONG CITY FUZHENGTANG BIOLOGICAL PRODUCTS FACTORY PHARMACEUTICAL PREPARATIONS QIDONG COUNTY HONGCHENGQITEDONGWU DRUG FACTORY PHARMACEUTICAL PREPARATIONS QIDONG COUNTY JUNRU PHARMACEUTICAL CO., LTD. PHARMACEUTICAL PREPARATIONS QIDONG COUNTY TAIYANG PLANTS RESOURCE COMPANY PHARMACEUTICAL PREPARATIONS QIDONG DONGYUE PHARMACEUTICAL CO., LTD. MEDICINALS AND BOTANICALS, NSK QIDONG FUZHENGTANG BIOLOGICAL TECHNOLOGY CO., LTD. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC QIDONG HAICHENG CHEMICAL CO., LTD. MEDICINALS AND BOTANICALS, NSK QIDONG HAILONG CHEMICAL INDUSTRY CO., LTD. PHARMACEUTICAL PREPARATIONS QIDONG JIAFENG MEDICINE TECHNOLOGY CO., LTD. PHARMACEUTICAL PREPARATIONS QIDONG JINHUI CHEMICAL CO., LTD. PHARMACEUTICAL PREPARATIONS QIDONG JIUFENG INDUSTRY & TRADE CO., LTD. MEDICINALS AND BOTANICALS, NSK QIDONG PHARMACEUTICAL MACHINERY FACTORY CO., LTD. MEDICINALS AND BOTANICALS, NSK QIDONG TIANHE BIOLOGIC PRODUCTS CO., LTD. PHARMACEUTICAL PREPARATIONS QIDONG WANGSHUN CHEMICAL CO., LTD. MEDICINALS AND BOTANICALS, NSK QIDU PHARMACEUTICAL CO., LTD. PHARMACEUTICAL PREPARATIONS QIFEN (SHANGHAI) BIOTECHNOLOGY CO., LTD. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC QIHE COUNTY DE'AO MEDICINE INTERMEDIATE CO., LTD. PHARMACEUTICAL PREPARATIONS QIHE QIJIA SPIRULINA BIOLOGY FOODSTUFF CO., LTD. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC QIJI COMMERCE AND TRADE INVESTMENT GROUP HUNAN COMPANY PHARMACEUTICAL PREPARATIONS QIKANGHABOWEIYAO CO., LTD. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC QILI TONGYUAN PHARMACEUTICAL CO., LTD. PHARMACEUTICAL PREPARATIONS QILIN BIOLOGICAL TECHNOLOGY CO., LTD. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC QILU ANTIBIOTICS (LINYI) PHARMACEUTICAL CO., LTD. PHARMACEUTICAL PREPARATIONS QILU ANTIBIOTICS PHARMACEUTICAL CO., LTD. MEDICINALS AND BOTANICALS, NSK QILU PHARMACEUTICAL (HAINAN) CO., LTD. PHARMACEUTICAL PREPARATIONS QILU PHARMACEUTICAL CO., LTD. PHARMACEUTICAL PREPARATIONS QILU PHARMACEUTICAL FACTORY PHARMACEUTICAL PREPARATIONS QILU PHARMACEUTICAL GROUP GENERAL COMPANY PHARMACEUTICAL PREPARATIONS QILU SYNVA PHARMACEUTICAL CO., LTD. PHARMACEUTICAL PREPARATIONS QILU TIANHE PHARMACEUTICAL CO., LTD. MEDICINALS AND BOTANICALS, NSK QIMAO BIOMEDICAL TECHNOLOGY CO., LTD. PHARMACEUTICAL PREPARATIONS QIMEN COUNTY PHARMACEUTICAL FACTORY MEDICINALS AND BOTANICALS, NSK QIMING PHARMACEUTICAL CO., LTD. MEDICINALS AND BOTANICALS, NSK QINDAO NO.2 ANIMAL MEDICINE FACTORY BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC QING COUNTY JIANMIN MOUTH CLINIC PHARMACEUTICAL PREPARATIONS QING COUNTY YULOU PRECISE MACHINE SCREEN FACTORY MEDICINALS AND BOTANICALS, NSK QING TOWN YINGLI PHARMACEUTICAL CO., LTD. PHARMACEUTICAL PREPARATIONS QING'AN PHARMACEUTICAL STOCK CO., LTD. PHARMACEUTICAL PREPARATIONS QINGCHUN BAOYIKE BIOLOGICAL MEDICINE CO., LTD. PHARMACEUTICAL PREPARATIONS QINGDAO AIMEI RUISHENG TECHNOLOGY CO., LTD. PHARMACEUTICAL PREPARATIONS QINGDAO AMERICA YAPEI PHARMACEUTICAL COMPANY PHARMACEUTICAL PREPARATIONS QINGDAO AOHAI BIOLOGY CO., LTD. PHARMACEUTICAL PREPARATIONS QINGDAO AOHAI ECOLOGICAL TECHNOLOGY CO., LTD. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC QINGDAO AOLAN BAITE BIO-ENGINEERING CO., LTD. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC QINGDAO AONUO PHARMACEUTICAL CO., LTD. PHARMACEUTICAL PREPARATIONS QINGDAO BAIHE FENGHUA BIOLOGICAL ENGINEERING CO., LTD. PHARMACEUTICAL PREPARATIONS QINGDAO BAILIAN BIOLOGICAL TECHNOLOGY CO., LTD. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC QINGDAO BAITEQI BIOLOGICAL ENGINEERING CO., LTD. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC QINGDAO BAIYANG PHARMACEUTICAL CO., LTD. PHARMACEUTICAL PREPARATIONS QINGDAO BANGDE PACKING CO., LTD. PHARMACEUTICAL PREPARATIONS QINGDAO BANGNI BIO-TECHNOLOGY CO., LTD. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC QINGDAO BAO'ERKANG TECHNOLOGY DEVELOPMENT CO., LTD. PHARMACEUTICAL PREPARATIONS QINGDAO BAOYITE BIOLOGICAL PHARMACEUTICAL CO., LTD. PHARMACEUTICAL PREPARATIONS QINGDAO BEIHAI ANIMAL REMEDY CO., LTD. PHARMACEUTICAL PREPARATIONS QINGDAO BETTER BIOLOGICAL TECHNOLOGY CO., LTD. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC QINGDAO BISHUIHANTIAN BIOLOGICAL CO., LTD. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC QINGDAO BNP BIOCHEMICAL TECHNOLOGY CO., LTD. PHARMACEUTICAL PREPARATIONS QINGDAO BOLONG HEALTHY BIOLOGICAL CO., LTD. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC QINGDAO CHANGHONG KANGBAI BIOLOGICAL TECHNOLOGY CO., LTD. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC QINGDAO CHANGQING HEALTH CARE PRODUCTS CO., LTD. PHARMACEUTICAL PREPARATIONS QINGDAO CHENGXUAN BIOLOGICAL TECHNOLOGY CO., LTD. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC QINGDAO CHIA TAI HAIER PHARMACEUTICAL CO., LTD. PHARMACEUTICAL PREPARATIONS QINGDAO COASTAL BIOLOGICAL PROTEIN CO., LTD. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC QINGDAO DAFUCHENG ANIMAL PHARMACEUTICAL CO., LTD. MEDICINALS AND BOTANICALS, NSK QINGDAO DAJIANKANG CULTURE COMMUNICATION CO., LTD. MEDICINALS AND BOTANICALS, NSK QINGDAO DALIAN SANYI ANIMAL DRUG CO., LTD. PHARMACEUTICAL PREPARATIONS QINGDAO DAMING HEALTH PRODUCTS CO., LTD. PHARMACEUTICAL PREPARATIONS QINGDAO DAQIN RUBBER BELT CO., LTD. MEDICINALS AND BOTANICALS, NSK QINGDAO DELIYA INTERNATIONAL TRADE CO., LTD. PHARMACEUTICAL PREPARATIONS QINGDAO DEMEIXIN PHARMACEUTICAL CO., LTD. PHARMACEUTICAL PREPARATIONS QINGDAO DEQINGXIANG IMPORT & EXPORT CO., LTD. MEDICINALS AND BOTANICALS, NSK QINGDAO DONGFANG PHARMACEUTICAL CO., LTD. PHARMACEUTICAL PREPARATIONS QINGDAO DONGFANG SHENGZHI CHINESE TRADITIONAL MEDICINE TECHNOLOGY CO., LTD. PHARMACEUTICAL PREPARATIONS QINGDAO ENNI HEALTH PRODUCT CO., LTD. PHARMACEUTICAL PREPARATIONS QINGDAO FENGYE BIOLOGY TECHNOLOGY CO.,LTD. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC QINGDAO FUCHENG BIOLOGICAL HEALTH PRODUCT CO., LTD. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC QINGDAO FUKA SEA TECHNOLOGY BIOLOGY CO., LTD. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC QINGDAO FUKANG DEER INDUSTRY PRODUCTS CO., LTD. PHARMACEUTICAL PREPARATIONS QINGDAO FURUIKANG ANIMAL HEALTH CARE CO., LTD. PHARMACEUTICAL PREPARATIONS QINGDAO GAODUAN BIOLOGICAL TECHNOLOGY CO., LTD. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC QINGDAO GD BIOLOGICAL TECHNOLOGY CO., LTD. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC QINGDAO GERUI PHARMACEUTICAL CO., LTD. PHARMACEUTICAL PREPARATIONS QINGDAO GRENADA PHARMACEUTICAL CO., LTD. PHARMACEUTICAL PREPARATIONS QINGDAO GROWFUL HI-TECH MEDICINE CO., LTD. PHARMACEUTICAL PREPARATIONS QINGDAO GUANGYUAN BIO-TECHNOLOGY CO., LTD. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC QINGDAO GUIDONG BIOLOGICAL TECHNOLOGY CO., LTD. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC QINGDAO GUODA POLYPEPTIDE REAGENT CO., LTD. PHARMACEUTICAL PREPARATIONS QINGDAO GUOFENG DONGRUI PHARMACEUTICAL CO., LTD. PHARMACEUTICAL PREPARATIONS QINGDAO GUOFENG GROUP JINHAI MEDICINE PROCUCTION CO., LTD. PHARMACEUTICAL PREPARATIONS QINGDAO GUOFENG GROUP TIANHE PHARMACEUTICAL SHINAN BRANCH COMPANY PHARMACEUTICAL PREPARATIONS QINGDAO GUOFENG WEI'AO PHARMACEUTICAL CO., LTD. PHARMACEUTICAL PREPARATIONS QINGDAO GUOTAI ( GROUP ) CO., LTD. PHARMACEUTICAL PREPARATIONS QINGDAO HAICHEN BIOLOGICAL TECHNOLOGY CO., LTD. PHARMACEUTICAL PREPARATIONS QINGDAO HAIDELONG BIOLOGICAL TECHNOLOGY CO., LTD. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC QINGDAO HAILILAI BIOTECHNOLOGY CO., LTD. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC QINGDAO HAIQIPU OCEAN BIOLOGICAL TECHNOLOGY DEVELOPMENT CO., LTD. BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC
Load more

Recommended publications
  • Appendix 1: Rank of China's 338 Prefecture-Level Cities
    Appendix 1: Rank of China’s 338 Prefecture-Level Cities © The Author(s) 2018 149 Y. Zheng, K. Deng, State Failure and Distorted Urbanisation in Post-Mao’s China, 1993–2012, Palgrave Studies in Economic History, https://doi.org/10.1007/978-3-319-92168-6 150 First-tier cities (4) Beijing Shanghai Guangzhou Shenzhen First-tier cities-to-be (15) Chengdu Hangzhou Wuhan Nanjing Chongqing Tianjin Suzhou苏州 Appendix Rank 1: of China’s 338 Prefecture-Level Cities Xi’an Changsha Shenyang Qingdao Zhengzhou Dalian Dongguan Ningbo Second-tier cities (30) Xiamen Fuzhou福州 Wuxi Hefei Kunming Harbin Jinan Foshan Changchun Wenzhou Shijiazhuang Nanning Changzhou Quanzhou Nanchang Guiyang Taiyuan Jinhua Zhuhai Huizhou Xuzhou Yantai Jiaxing Nantong Urumqi Shaoxing Zhongshan Taizhou Lanzhou Haikou Third-tier cities (70) Weifang Baoding Zhenjiang Yangzhou Guilin Tangshan Sanya Huhehot Langfang Luoyang Weihai Yangcheng Linyi Jiangmen Taizhou Zhangzhou Handan Jining Wuhu Zibo Yinchuan Liuzhou Mianyang Zhanjiang Anshan Huzhou Shantou Nanping Ganzhou Daqing Yichang Baotou Xianyang Qinhuangdao Lianyungang Zhuzhou Putian Jilin Huai’an Zhaoqing Ningde Hengyang Dandong Lijiang Jieyang Sanming Zhoushan Xiaogan Qiqihar Jiujiang Longyan Cangzhou Fushun Xiangyang Shangrao Yingkou Bengbu Lishui Yueyang Qingyuan Jingzhou Taian Quzhou Panjin Dongying Nanyang Ma’anshan Nanchong Xining Yanbian prefecture Fourth-tier cities (90) Leshan Xiangtan Zunyi Suqian Xinxiang Xinyang Chuzhou Jinzhou Chaozhou Huanggang Kaifeng Deyang Dezhou Meizhou Ordos Xingtai Maoming Jingdezhen Shaoguan
    [Show full text]
  • World Bank Document
    Public Disclosure Authorized Public Disclosure Authorized Goods and Works Procurement Plan in 2007 2007 Name of Subproject: Nuisance Free Vegetable, Changsha County ( Review by Issuing of Bid Contract Cost estimate Procurement P- Contract No. Bank BD opening signing Contract Description method Q USD ( RMB (Y/N) Equivalent Y/N) Works Public Disclosure Authorized Public Disclosure Authorized Vegetable processing 800 NCB Hn workshop 800 , Vegetable 300 à à 1 1 à à à quality test room 300 NCB GJP 80 type plastic sheds GJP80 Hn à à 1 1 à à à 42979 42979 m2 Subtotal à à Goods Public Disclosure Authorized Public Disclosure Authorized 1 Public Disclosure Authorized Public Disclosure Authorized Goods and Works Procurement Plan in 2007 2007 Name of Subproject: Nuisance Free Vegetable, Changsha County ( Review by Issuing of Bid Contract Cost estimate Procurement P- Contract No. Bank BD opening signing Contract Description method Q USD ( RMB (Y/N) Equivalent Y/N) Vegetable Test Devices, including: dehumidifiers 4sets, air conditioners 4sets, refrigerators 4sets, fresh- keeping refrigerated cabinets 4sets, ultrasonic cleaners 3sets, centrifuges 3sets, drying cabinets 3sets, stainless steel electrical distillers 6sets, rotary evaporators 4sets, rapid 16 Hn à à 1 1 detector of pesticide residues 6sets, residual pesticide meters 6sets, full automatic thermo wellwash plus 1sets, electro-heating constant temperature cultivators 6sets, 3+ multifunctional vibrators 6sets, precise PH meters 6sets, freezing dryers 6sets, spiral slice vacuum
    [Show full text]
  • Land-Use Efficiency in Shandong (China)
    sustainability Article Land-Use Efficiency in Shandong (China): Empirical Analysis Based on a Super-SBM Model Yayuan Pang and Xinjun Wang * Department of Environmental Science and Engineering, Fudan University, Shanghai 200433, China; [email protected] * Correspondence: [email protected] Received: 20 November 2020; Accepted: 14 December 2020; Published: 18 December 2020 Abstract: A reasonable evaluation of land-use efficiency is an important issue in land use and development. By using a super-SBM model, the construction and cultivated land-use efficiency of 17 cities in Shandong from 2006 to 2018 were estimated and the spatial-temporal variation was analyzed. The results showed that: (1) The land use efficiency levels were quite different, and low-efficiency cities impacted the overall development process. (2) The efficiency values of construction land generally fluctuated and rose, meaning that room remains for future efficiency improvements. Cultivated land generally showed a high utilization efficiency, but it fluctuated and decreased. (3) The construction land-use efficiency was highest in the midland region, especially in Laiwu city, followed by the eastern region and Qingdao city, and the western region. The spatial variation in cultivated land presented a trend of “high in the middle, low in the periphery,” centered on Jinan and Yantai city. (4) Pure technical efficiency was the main restriction driving inefficient utilization in the western region, while scale efficiency played that role in the east. Based on the findings, policy suggestions were proposed to improve the land-use efficiency in Shandong and promote urban sustainable development. Keywords: land use; efficiency level; super-SBM model; Shandong Province; construction land; cultivated land 1.
    [Show full text]
  • Environmental Impact Analysis in This Report
    Environmental Impacts Assessment Report on Project Construction Project name: European Investment Bank Loan Hunan Camellia Oil Development Project Construction entity (Seal): Foreign Fund Project Administration Office of Forestry Department of Hunan Province Date of preparation: July 1st, 2012 Printed by State Environmental Protection Administration of China Notes for Preparation of Environmental Impacts Assessment Report on Project Construction An Environmental Impacts Assessment (EIA) Report shall be prepared by an entity qualified for conducting the work of environmental impacts assessment. 1. Project title shall refer to the name applied by the project at the time when it is established and approved, which shall in no case exceed 30 characters (and every two English semantic shall be deemed as one Chinese character) 2. Place of Construction shall refer to the detailed address of project location, and where a highway or railway is involved, names of start station and end station shall be provided. 3. Industry category shall be stated according to the Chinese national standards. 4. Total Investment Volume shall refer to the investment volume in total of the project. 5. Principal Targets for Environment Protection shall refer to centralized residential quarters, schools, hospitals, protected culture relics, scenery areas, water sources and ecological sensitive areas within certain radius of the project area, for which the objective, nature, size and distance from project boundary shall be set out as practical as possible. 6. Conclusion and suggestions shall include analysis results for clean production, up-to-standard discharge and total volume control of the project; a determination on effectiveness of pollution control measures; an explanation on environmental impacts by the project, and a clear-cut conclusion on feasibility of the construction project.
    [Show full text]
  • Beijing Baidu Netcom Science and Technology Co., Ltd
    Beijing Baidu Netcom Science and Technology Co., Ltd. v. Qingdao Aoshang Network Technology Co., Ltd. et al., An Unfair Competition Dispute Guiding Case No. 45 (Discussed and Passed by the Adjudication Committee of the Supreme People’s Court Released on April 15, 2015) CHINA GUIDING CASES PROJECT English Guiding Case (EGC45) November 15, 2015 Edition * * The citation of this translation of the Guiding Case is: 《北京百度网讯科技有限公司诉青岛奥商网络技 术有限公司等不正当竞争纠纷案》 (Beijing Baidu Netcom Science and Technology Co., Ltd. v. Qingdao Aoshang Network Technology Co., Ltd., An Unfair Competition Dispute ), CHINA GUIDING CASES PROJECT , English Guiding Case (EGC45), Nov. 15, 2015 Edition , available at http://cgc.law.stanford.edu/guiding -cases/guiding -case -45. This document was primarily prepared by Jasmine Chen, Jeffrey Chivers, Oma Lee, Jeremy Schlosser, Yifan Yang, and Shiyue Zhang. The document was finalized by Sean Webb, Jordan Corrente Beck, and Dr. Mei Gechlik. Minor editing, such as splitting long paragraphs, adding a few words included in square brackets, and boldfacing the headings to correspond with those boldfaced in the original Chinese version, was done to make the piece more comprehensible to readers. The following text, otherwise, is a direct translation of the original text and reflects the formatting of the Chinese document released by the Supreme People’s Court. The following Guiding Case was discussed and passed by the Adjudication Committee of the Supreme People’s Court of the People’s Republic of China and was released on April 15, 2015, available at http://www.chinacourt.org/article/detail/2015/04/id/1602323.shtml. See also 《最高人民法院关于发布第十批指 导性案例的通知》 (The Supreme People’s Court’s Notice Concerning the Release of the Tenth Batch of Guiding Cases ), Apr.
    [Show full text]
  • Table of Codes for Each Court of Each Level
    Table of Codes for Each Court of Each Level Corresponding Type Chinese Court Region Court Name Administrative Name Code Code Area Supreme People’s Court 最高人民法院 最高法 Higher People's Court of 北京市高级人民 Beijing 京 110000 1 Beijing Municipality 法院 Municipality No. 1 Intermediate People's 北京市第一中级 京 01 2 Court of Beijing Municipality 人民法院 Shijingshan Shijingshan District People’s 北京市石景山区 京 0107 110107 District of Beijing 1 Court of Beijing Municipality 人民法院 Municipality Haidian District of Haidian District People’s 北京市海淀区人 京 0108 110108 Beijing 1 Court of Beijing Municipality 民法院 Municipality Mentougou Mentougou District People’s 北京市门头沟区 京 0109 110109 District of Beijing 1 Court of Beijing Municipality 人民法院 Municipality Changping Changping District People’s 北京市昌平区人 京 0114 110114 District of Beijing 1 Court of Beijing Municipality 民法院 Municipality Yanqing County People’s 延庆县人民法院 京 0229 110229 Yanqing County 1 Court No. 2 Intermediate People's 北京市第二中级 京 02 2 Court of Beijing Municipality 人民法院 Dongcheng Dongcheng District People’s 北京市东城区人 京 0101 110101 District of Beijing 1 Court of Beijing Municipality 民法院 Municipality Xicheng District Xicheng District People’s 北京市西城区人 京 0102 110102 of Beijing 1 Court of Beijing Municipality 民法院 Municipality Fengtai District of Fengtai District People’s 北京市丰台区人 京 0106 110106 Beijing 1 Court of Beijing Municipality 民法院 Municipality 1 Fangshan District Fangshan District People’s 北京市房山区人 京 0111 110111 of Beijing 1 Court of Beijing Municipality 民法院 Municipality Daxing District of Daxing District People’s 北京市大兴区人 京 0115
    [Show full text]
  • Bangladesh Chittagong China Hong Kong Shenzhen
    Japan Tokyo 14 Dalian Seoul 15 Yokohama 17 South 13 Tianjin 8 16 Korea 12 Osaka-wan 10 Inch'on Kobe 7 6 9 Beijing Qingdao Busan Australia Australia 34 Brisbane 34 Brisbane Australia Australia 3 Shanghai Australia Brisbane 34 34 Brisbane 34 Brisbane China Taipei Australia Brisbane 29 34 New Delhi 21 Australia Taiwan Brisbane 5 Kao-hsiung Sydney 34 Guangzhou 32 Sydney 11 Perth 32 Hong Kong 36 Adelaide 2 Perth Bangladesh 36 35 Adelaide 4 35 Shenzhen Sydney Sydney Chittagong Sydney 32 32 Nagpur 23 Perth Perth Adelaide 32 18 Perth 36 36 Adelaide Mumbai (Bombay) 20 Philippines 36 Adelaide 35 35 Manila 27 Melbourne35 India 33 Melbourne 33 Sydney 32 Perth Thailand 36 Adelaide Sydney Auckland 35 Melbourne 32 Melbourne Vietnam Perth Melbourne 33 33 37 Auckland Bangkok 30 36 Adelaide33 37 Bangalore 22 19 Chennai (Madras) 35 31 Ho Chi Minh City Auckland Auckland Auckland 37 37 Melbourne New Zealand 37 33 New Zealand Melbourne Colombo 28 Sri Lanka Main Transport Terminals Trade(import-export) value Population (million people) 33 Malaysia Connections (billion US dollars) in 2007 AucklandNew Zealand 37 New Zealand Kuala Lumpur New Zealand Road Asia Highway >1000 0 - 2 Auckland 25 Network 37 26 Port of Tanjung 1 Indonesia International Airport 500 - 1000 2 - 5 Pelepas Singapore River New Zealand Sea Harbour 100 - 500 5 - 10 New Zealand River Harbour <100 0 245 490 Miles > 10 Free Economic Zone Jakarta 24 0 245 490 KM 1. Singapore 2. Hong Kong 3. Shanghai 4. Shenzhen 5. Kaohsiung 6. Busan 7. Beijing 8. Dalian Singapore is the world’s biggest container port with yearly throughput Hong Kong is a hub port serving the South Asian Pacific region and Shanghai is the power house for the economic growth of China.
    [Show full text]
  • Addition of Clopidogrel to Aspirin in 45 852 Patients with Acute Myocardial Infarction: Randomised Placebo-Controlled Trial
    Articles Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group* Summary Background Despite improvements in the emergency treatment of myocardial infarction (MI), early mortality and Lancet 2005; 366: 1607–21 morbidity remain high. The antiplatelet agent clopidogrel adds to the benefit of aspirin in acute coronary See Comment page 1587 syndromes without ST-segment elevation, but its effects in patients with ST-elevation MI were unclear. *Collaborators and participating hospitals listed at end of paper Methods 45 852 patients admitted to 1250 hospitals within 24 h of suspected acute MI onset were randomly Correspondence to: allocated clopidogrel 75 mg daily (n=22 961) or matching placebo (n=22 891) in addition to aspirin 162 mg daily. Dr Zhengming Chen, Clinical Trial 93% had ST-segment elevation or bundle branch block, and 7% had ST-segment depression. Treatment was to Service Unit and Epidemiological Studies Unit (CTSU), Richard Doll continue until discharge or up to 4 weeks in hospital (mean 15 days in survivors) and 93% of patients completed Building, Old Road Campus, it. The two prespecified co-primary outcomes were: (1) the composite of death, reinfarction, or stroke; and Oxford OX3 7LF, UK (2) death from any cause during the scheduled treatment period. Comparisons were by intention to treat, and [email protected] used the log-rank method. This trial is registered with ClinicalTrials.gov, number NCT00222573. or Dr Lixin Jiang, Fuwai Hospital, Findings Allocation to clopidogrel produced a highly significant 9% (95% CI 3–14) proportional reduction in death, Beijing 100037, P R China [email protected] reinfarction, or stroke (2121 [9·2%] clopidogrel vs 2310 [10·1%] placebo; p=0·002), corresponding to nine (SE 3) fewer events per 1000 patients treated for about 2 weeks.
    [Show full text]
  • Annual Report 2000 Corporate Structure
    CHARACTERISTICS OF THE GROWTH ENTERPRISE MARKET (“GEM”) OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE “EXCHANGE”) GEM has been established as a market designed to accommodate companies to which a high investment risk may be attached. In particular, companies list on GEM with neither track record of profitability nor any obligation forecast future profitability. Furthermore, there may be risks arising out of the emerging nature of companies listed on GEM and the business sectors or countries in which the companies operate. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration. The greater risk profile and other characteristics of GEM mean that it is a market more suited to professional and other sophisticated investors. Given the emerging nature of companies listed on GEM, there is a risk that securities traded on GEM may be more susceptible to highmarket volatility than securities traded on the Main Board and no assurance is given that there will be a liquid market in the securities traded on GEM. The principal means of information dissemination on GEM is publication on the internet website operated by the Exchange. Listed companies are not generally required to issue paid announcements in gazetted newspapers. Accordingly, prospective investors should note that they need to have access to the GEM website in order to obtain up-to-date information on GEM-listed issuers. Contents Corporate Information 2 Corporate Structure
    [Show full text]
  • Research on Layout of Multimodal Transport Center in Jinan City
    E3S Web of Conferences 38, 01040 (2018) https://doi.org/10.1051/e3sconf/20183801040 ICEMEE 2018 Research on layout of multimodal transport center in Jinan City Xue Qin ZHANG 1,*, Ying Ran CUI 1, Yuan LI 1 ,and Xiu Feng LIANG 1 1Shandong Jiaotong University, Ji’nan, Shandong 250300, China Abstract. Multimodal operation is an efficient form of transportation organization. By integrating various modes of transport, the advantages of each mode are fully exerted, and the efficiency and quality of transportation are improved to meet the demand for personalized transport. This article first analyzes the status of multimodal transport development in various regions of Shandong Province; through the analysis of the external environment in which Jinan City is located, it proposes the layout of the Jinan Multimodal Transport Center; finally, it proposes various solutions based on the actual development status. 1 Introduction Table.1 2011-2017Shandong Province GDP and industrial With the development of society, people pay more and structure ratio more attention to the efficiency of transport. In this case, Years GDP/ Billion The proportion of multimodal transport has emerged as the times require. It three industries depends on the combination of sea and land, land and 2011 45429.2 8.8:52.9:38.3 land, and so on, which greatly reduces the transportation 2012 50013.2 8.6:51.4:40.0 time and saves manpower. Most multimodal transport 2013 54684.3 8.7:50.1:41.2 today relies on large containers for loading and 2014 59426.6 8.1:48.4:43.5 unloading of goods.
    [Show full text]
  • About Shandong
    About Shandong People's Government of Shandong Province Administrative division As at December 31, 2017, the investigation land area of Shandong Province totaled 157,965km2. By the end of 2017, the total population of Shandong was 100,058,300. By December 31, 2017, Shandong Province had jurisdiction over 17 prefecture-level cities including Ji’nan, Qingdao, Zibo, Zaozhuang, Dongying, Yantai, Weifang, Ji’ning, Tai'an, Weihai, Rizhao, Laiwu, Linyi, Dezhou, Liaocheng, Binzhou and Heze, covering 137 county-level units and 1,824 township-level administrative units. Geological resources [Location & area] Shandong Province is located on the eastern coast of China and the lower reaches of the Yellow River, between 34°22.9′~38°24.01′N and 114°47.5′~122°42.3′E. The territory is composed of the peninsula and inland. The Shandong Peninsula stands out in the Bohai Sea and the Yellow Sea, facing the Liaodong Peninsula. The inland part is bordered by Hebei, He’nan, Anhui and Jiangsu provinces from the north to the south. The territory is about 420km long from north to south and around 700km wide from east to west, with a total area of 157,100km2, accounting for 1.64% of the total area of China, The capital of Shandong Province is Ji’nan. [Terrain & landform] The terrain of the province is composed of mountains in the center and basins and plains in the northwest and the northwest, forming a landform of mountainous & hills as the skeleton and the plains & basins interlaced. The mountain area accounts for 15.5% of the total area of the province, hills 13.2%, plains 55%, lowlands 4.1%, lakes & plains 4.4%, and others 7.8%.
    [Show full text]
  • Analysis of Spatial-Temporal Distribution of Notifiable Respiratory
    Li et al. BMC Public Health (2021) 21:1597 https://doi.org/10.1186/s12889-021-11627-6 RESEARCH ARTICLE Open Access Analysis of spatial-temporal distribution of notifiable respiratory infectious diseases in Shandong Province, China during 2005– 2014 Xiaomei Li1†, Dongzhen Chen1,2†, Yan Zhang3†, Xiaojia Xue4, Shengyang Zhang5, Meng Chen6, Xuena Liu1* and Guoyong Ding1* Abstract Background: Little comprehensive information on overall epidemic trend of notifiable respiratory infectious diseases is available in Shandong Province, China. This study aimed to determine the spatiotemporal distribution and epidemic characteristics of notifiable respiratory infectious diseases. Methods: Time series was firstly performed to describe the temporal distribution feature of notifiable respiratory infectious diseases during 2005–2014 in Shandong Province. GIS Natural Breaks (Jenks) was applied to divide the average annual incidence of notifiable respiratory infectious diseases into five grades. Spatial empirical Bayesian smoothed risk maps and excess risk maps were further used to investigate spatial patterns of notifiable respiratory infectious diseases. Global and local Moran’s I statistics were used to measure the spatial autocorrelation. Spatial- temporal scanning was used to detect spatiotemporal clusters and identify high-risk locations. Results: A total of 537,506 cases of notifiable respiratory infectious diseases were reported in Shandong Province during 2005–2014. The morbidity of notifiable respiratory infectious diseases had obvious seasonality with high morbidity in winter and spring. Local Moran’s I analysis showed that there were 5, 23, 24, 4, 20, 8, 14, 10 and 7 high-risk counties determined for influenza A (H1N1), measles, tuberculosis, meningococcal meningitis, pertussis, scarlet fever, influenza, mumps and rubella, respectively.
    [Show full text]